LeonaBio (LONA) director entities receive 28,000 stock options grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
LeonaBio, Inc. reported a Form 4 showing an option grant related to director compensation. Entities associated with director Joseph Edelman received a stock option covering 28,000 shares of common stock at an exercise price of $8.35 per share. The option vests on the earlier of June 23, 2027 or the day before the next annual stockholder meeting after June 22, 2026, and expires on June 22, 2036. The grant was made under LeonaBio’s Outside Director Compensation Policy, with Perceptive entities having an indirect pecuniary interest through a management fee offset and disclaiming beneficial ownership except to that extent.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
PERCEPTIVE ADVISORS LLC, EDELMAN JOSEPH, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
Role
Director, 10% Owner | Director, 10% Owner | Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 28,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 28,000 shares (Indirect, See footnote)
Footnotes (1)
- The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Joseph Edelman ("Mr. Edelman") is the managing member of Perceptive Advisors LLC (the "Advisor"). The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor may be deemed to have an indirect pecuniary interest in the securities reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Edelman's board service through a partial management fee offset. Each of the Master Fund and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that either the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Key Figures
Option grant size: 28,000 shares
Exercise price: $8.35 per share
Expiration date: June 22, 2036
+1 more
4 metrics
Option grant size
28,000 shares
Stock option covering LeonaBio common stock
Exercise price
$8.35 per share
Strike price for the stock option grant
Expiration date
June 22, 2036
Option term end date
Vesting date trigger
Earlier of June 23, 2027 or pre-next annual meeting
Option vesting schedule conditions
Key Terms
Stock Option (Right to Buy), Outside Director Compensation Policy, indirect pecuniary interest, beneficial ownership, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Outside Director Compensation Policy financial
"The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy"
indirect pecuniary interest financial
"The Advisor may be deemed to have an indirect pecuniary interest in the securities reported herein"
beneficial ownership regulatory
"disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 of the Securities Exchange Act of 1934 regulatory
"for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
FAQ
What insider transaction did LeonaBio (LONA) report in this Form 4?
LeonaBio reported a grant of stock options covering 28,000 shares of common stock to entities tied to director Joseph Edelman. The options were issued as part of the company’s Outside Director Compensation Policy for his board service.
What is the exercise price and size of the LeonaBio (LONA) option grant?
The option grant covers 28,000 shares of LeonaBio common stock at an exercise price of $8.35 per share. This means the holder may buy shares at $8.35 once the options vest, regardless of future market price.
When do the LeonaBio (LONA) director stock options vest and expire?
The options vest on the earlier of June 23, 2027, or the day before LeonaBio’s next annual stockholder meeting held after June 22, 2026. They expire on June 22, 2036, if not exercised before that date.
Who holds the LeonaBio (LONA) options reported in this filing?
The options are held indirectly through Perceptive Advisors LLC and Perceptive Life Sciences Master Fund Ltd, which are associated with director Joseph Edelman. These entities may have an indirect pecuniary interest through a management fee offset mechanism.
How do Perceptive entities describe their ownership in this LeonaBio (LONA) filing?
Perceptive Life Sciences Master Fund Ltd and Perceptive Advisors LLC disclaim beneficial ownership of the reported securities, except for their indirect pecuniary interest. They note that compensation is received via a partial management fee offset tied to Joseph Edelman’s board role.